Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Eltrekibart in Moderate to Severe Hidradenitis Suppurativa
2023-505608-43-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Anti-inflammatory mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Eltrekibart with Placebo (2 arms). Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 (HiSCR50). Started Jul 2024; status: completed.
02
Drugs
eltrekibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-505608-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505608-43-00.